Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinoma

1 Mar 2023

Abstract excerpt

Background: Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer (NSCLC) with poor survival in advanced stage. Nowadays the rate of nonsmoking patients has dramatically increased and may be associated with the presence of driver mutations. Better understanding of the mutation profile data of nonsmoking LUAD patients are critical to predict survival and provide greater benefits to more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis
Share to interferon and immune responses
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37057114
DOI: 10.21037/tlcr-23-150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOBEC mutational signature predicts prognosis and immunotherapy response in nonsmoking patients with lung adenocarcinomaPMID 37057114Read ↗

APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.Semantic proximity Read ↗

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancerSemantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Semantic proximity Read ↗

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.Semantic proximity Read ↗

APOBEC shapes tumor evolution and age at onset of lung cancer in smokersSemantic proximity Read ↗

Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell CarcinomaSemantic proximity Read ↗

APOBEC Alteration Contributes to Tumor Growth and Immune Escape in Pan-CancerSemantic proximity Read ↗

Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

An overview of the functions and mechanisms of APOBEC3A in tumorigenesisSemantic proximity Read ↗

A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokersSemantic proximity Read ↗

Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.